Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 6 days & Counting

PTSC has slowly ground any MMP dialogue (to its shareholders) to a halt while TPL is supposedly up for sale, running the risk of violating the master agreement, embroiled in an ownership disagreement with Moore, and leaving the financial litigation mess possibly dropped into PTSC's lap? Is DL looking for a nuisance fee to step out of the way since the only logical choice would be PTSC? Would that force new agreements with Moore? With every patent victory, wouldn't that increase DL's price assuming cost of operations isn't a factor? Would a picture with TPL out of the way, clear a path towards revamping the BOD considering the 27 millionish Crossflo voting shares?.........

My T's & O's.......

Share
New Message
Please login to post a reply